Trial · NCT01668667
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 20
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| The Change From Baseline to the End of Treatment in the International Restless Legs Syndrome (IRLS) Rating Scale Score | GSK1838262 600 mg | -12.50 | Standard Error 0.745 | units on a scale | |
| The Change From Baseline to the End of Treatment in the International Restless Legs Syndrome (IRLS) Rating Scale Score | GSK1838262 450 mg | -12.54 | Standard Error 0.764 | units on a scale | |
| The Change From Baseline to the End of Treatment in the International Restless Legs Syndrome (IRLS) Rating Scale Score | GSK1838262 300 mg | -11.48 | Standard Error 0.767 | units on a scale | |
| The Change From Baseline to the End of Treatment in the International Restless Legs Syndrome (IRLS) Rating Scale Score | GSK1838262 Placebo Match | -9.93 | Standard Error 0.753 | units on a scale | |
| The Proportion of Subjects at the End of Treatment Who Are Responders With Either Much Improved or Very Much Improved on the Investigator-rated Clinical Global Impression of Improvement (CGI-I) | GSK1838262 600 mg | 67 | percentage of participants | ||
| The Proportion of Subjects at the End of Treatment Who Are Responders With Either Much Improved or Very Much Improved on the Investigator-rated Clinical Global Impression of Improvement (CGI-I) | GSK1838262 450 mg | 67 | percentage of participants | ||
| The Proportion of Subjects at the End of Treatment Who Are Responders With Either Much Improved or Very Much Improved on the Investigator-rated Clinical Global Impression of Improvement (CGI-I) | GSK1838262 300 mg | 68 | percentage of participants | ||
| The Proportion of Subjects at the End of Treatment Who Are Responders With Either Much Improved or Very Much Improved on the Investigator-rated Clinical Global Impression of Improvement (CGI-I) | GSK1838262 Placebo Match | 50 | percentage of participants | ||
| The Dose-response Relationship of Change From Baseline in IRLS Rating Scale Total Score at End of Treatment | GSK1838262 600 mg | -12.1 | Standard Error 0.80 | units on a scale | |
| The Dose-response Relationship of Change From Baseline in IRLS Rating Scale Total Score at End of Treatment | GSK1838262 450 mg | -12.7 | Standard Error 0.82 | units on a scale | |
| The Dose-response Relationship of Change From Baseline in IRLS Rating Scale Total Score at End of Treatment | GSK1838262 300 mg | -11.3 | Standard Error 0.83 | units on a scale | |
| The Dose-response Relationship of Change From Baseline in IRLS Rating Scale Total Score at End of Treatment | GSK1838262 Placebo Match | -9.8 | Standard Error 0.80 | units on a scale | |
| The Dose-response Relationship for Investigator-rated CGI-I Scale at End of Treatment | GSK1838262 600 mg | Responder | 67 | percentage of participants | |
| The Dose-response Relationship for Investigator-rated CGI-I Scale at End of Treatment | GSK1838262 450 mg | Responder | 67 | percentage of participants | |
| The Dose-response Relationship for Investigator-rated CGI-I Scale at End of Treatment | GSK1838262 300 mg | Responder | 68 | percentage of participants | |
| The Dose-response Relationship for Investigator-rated CGI-I Scale at End of Treatment | GSK1838262 Placebo Match | Responder | 50 | percentage of participants | |
| The Dose-response Relationship for Investigator-rated CGI-I Scale at End of Treatment | GSK1838262 600 mg | Non-Responder | 33 | percentage of participants | |
| The Dose-response Relationship for Investigator-rated CGI-I Scale at End of Treatment | GSK1838262 450 mg | Non-Responder | 33 | percentage of participants | |
| The Dose-response Relationship for Investigator-rated CGI-I Scale at End of Treatment | GSK1838262 300 mg | Non-Responder | 32 | percentage of participants | |
| The Dose-response Relationship for Investigator-rated CGI-I Scale at End of Treatment | GSK1838262 Placebo Match | Non-Responder | 50 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01668667/results